1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow ALLR3: new trials by email Literature Review of ALLR3 trials Research Report on ALLR3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL Inotuzumab ozogamicin, ALLR3 - ACUTE LYMPHOBLASTIC LEUKEMIA | Phase 2 | Recruiting | Pfizer | 100 | 2023-05-17 | 2026-09-24 |
Leukemia (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Pfizer (1)
Austria (1) · Belgium (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · Norway (1) · Slovakia (1) · Spain (1) · Sweden (1) · Switzerland (1)
2023 (1)